The results of an international, randomized, double-blind, placebo-controlled phase III clinical trial indicate that the addition of the androgen receptor inhibitor darolutamide to androgen deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer
The results of an international, randomized, double-blind, placebo-controlled phase III clinical trial indicate that the addition of the androgen receptor inhibitor darolutamide to androgen deprivation therapy and chemotherapy prolongs the survival of men with metastatic disease. hormone-sensitive cancer of the prostate. The study, which was conducted by a team of researchers at Massachusetts General Hospital (MGH), was published in the New England Journal of Med... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
If you already have an account, please log in
